- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 594-608 of
1,261 results
1115 Exhibit: Exhibit 1115 CDC Report
Document
IPR2023-00724, No. 1115 Exhibit - Exhibit 1115 CDC Report (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1178 Exhibit: Exhibit 1178 Novo Nordisk Annual Report 2007
Document
IPR2023-00724, No. 1178 Exhibit - Exhibit 1178 Novo Nordisk Annual Report 2007 (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1122 Exhibit: Exhibit 1122 ADA Standards 2023
Document
IPR2023-00724, No. 1122 Exhibit - Exhibit 1122 ADA Standards 2023 (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2535 Exhibit: EX2535 Declaration of Jenny C Wu
Document
IPR2023-00724, No. 2535 Exhibit - EX2535 Declaration of Jenny C Wu (P.T.A.B. Apr. 10, 2024)
|
|
Cite Document
2018 Exhibit: EX2018 Transcript of December 29, 2023 Deposition of John Bantle, ...
Document
IPR2023-00724, No. 2018 Exhibit - EX2018 Transcript of December 29, 2023 Deposition of John Bantle, MD (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2497 Exhibit: EX2497 Novo Nordisk, Financial report for the period 1 January 2018...
Document
IPR2023-00724, No. 2497 Exhibit - EX2497 Novo Nordisk, Financial report for the period 1 January 2018 to 31 December 2018 Feb 1, 2019 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2113 Exhibit: EX2113 Victoza® FDA Approval Letter Jan 25, 2010
Document
IPR2023-00724, No. 2113 Exhibit - EX2113 Victoza® FDA Approval Letter Jan 25, 2010 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2426 Exhibit: EX2426 Nesina® Prescribing Information rev Dec 2016
Document
IPR2023-00724, No. 2426 Exhibit - EX2426 Nesina® Prescribing Information rev Dec 2016 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2545 Exhibit: EX2545 Petitioners’ Motion for Joinder Under 35 USC 315c and 37 C...
Document
IPR2023-00724, No. 2545 Exhibit - EX2545 Petitioners’ Motion for Joinder Under 35 USC 315c and 37 CFR 4222 and 42122b, Dr Reddy’s Laboratories Inc v Novo Nordisk AS, IPR2024 00009, P...
|
|
Cite Document
2656 Exhibit: EX2656 July 12, 2024 Email Thread Among Counsel for Petitioners M...
Document
IPR2023-00724, No. 2656 Exhibit - EX2656 July 12, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft ...
|
|
Cite Document
2496 Exhibit: EX2496 Novo Nordisk, Financial report for the period 1 January 2018...
Document
IPR2023-00724, No. 2496 Exhibit - EX2496 Novo Nordisk, Financial report for the period 1 January 2018 to 30 September 2018 Nov 1, 2018 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2498 Exhibit: EX2498 Novo Nordisk, Financial report for the period 1 January 2019...
Document
IPR2023-00724, No. 2498 Exhibit - EX2498 Novo Nordisk, Financial report for the period 1 January 2019 to 31 March 2019 May 3, 2019 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2063 Exhibit: EX2063 OPTUMRx, “Tanzeum® albiglutide – Drug Discontinuation,” av...
Document
IPR2023-00724, No. 2063 Exhibit - EX2063 OPTUMRx, “Tanzeum® albiglutide – Drug Discontinuation,” available at httpsprofessionalsoptumrxcomcontentdamoptum3professional optumrxnewsr...
|
|
Cite Document
2394 Exhibit: EX2394 Mansfield, C, et al, Patient Preferences for Attributes of Type...
Document
IPR2023-00724, No. 2394 Exhibit - EX2394 Mansfield, C, et al, Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain An Online Discrete Choice Expe...
|
|
Cite Document
2352 Exhibit: EX2352 Mayo Clinic, “Diabetes – Symptoms causes,” httpswwwmayoc...
Document
IPR2023-00724, No. 2352 Exhibit - EX2352 Mayo Clinic, “Diabetes – Symptoms causes,” httpswwwmayoclinicorgdiseases conditionsdiabetessymptoms causessyc 20371444, last updated Sept...
|
|
Cite Document
